Citadel Advisors
THRD

Citadel Advisors’s Third Harmonic Bio THRD Stock Holding History

Citadel Advisors’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,800
Closed -$79.1K – 15063
2025
Q1 		$79.1K Buy
+22,800
New +$111K ﹤0.01% 11774

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $13.1B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Citadel Advisors's THRD Position: Q3 2025 in Review

Citadel Advisors sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 120,870 shares — an estimated $656K sold.

Citadel Advisors first reported a position in THRD in Q3 2022 and held it in 8 quarters. The position peaked at $8.85M in Q2 2024. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Citadel Advisors reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 120,870 Third Harmonic Bio shares in Q3 2025, an estimated $656K.
  • Citadel Advisors first reported a position in Third Harmonic Bio in Q3 2022 and held it in 8 quarters.
  • Citadel Advisors's Third Harmonic Bio position peaked at $8.85M in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.